Single-Centre Experience of Testosterone Therapy for Boys with Hypogonadism.
Hypogonadism in boys is one of the commonest conditions encountered in paediatric endocrinology. To study variations in management in a contemporary group of boys at a single specialist centre. Retrospective review of case records of all boys treated with testosterone at a tertiary endocrine service from 2012 to 2017. Of the 358 boys reviewed for hypogonadism, 46 (13%) were initiated on testosterone therapy at a median age (range) of 14.2 years (12.1, 17.7). Indications for therapy included a functional delay of puberty that was constitutional in 17 (37%) or related to chronic disease in 10 (22%) or organic hypogonadism due to primary gonadal failure in 7 (15%), multiple pituitary hormone deficiency in 6 (13%), and isolated hypogonadotropic hypogonadism in 6 (13%). Of the 46 boys, 40 (89%) were started on intramuscular testosterone, 4 (9%) on oral testosterone, and 1 (2%) on transdermal gel. Of the 19 boys (40%) with organic hypogonadism re-quiring long-term therapy, 12 (63%) had assessment of liver function, 6 (32%) had a haematocrit, and 2 (11%) had a DXA scan in the year of commencing treatment. Testosterone therapy is administered in about 13% of boys reviewed for hypogonadism and its monitoring requires standardisation.